Methods for predicting response to dna repair pathway inhibitors in diffuse large b-cell lymphoma
作者： Philippe Pasero , Guillaume Cartron , Jérôme Moreaux , Caroline Bret , Angelos Constantinou
DOI:
关键词:
摘要: The present invention relates to a method of testing whether patient suffering from arge B-cell lymphoma will respond or not DNA repair pathway inhibitor comprising: i) determining the expression level (ELi) several genes Gi-Gn selected table A in biological sample obtained said comparing determined at step with predetermined reference (ELRi) iii) calculating score trough following formula (I), wherein βi represent regression β coefficient value for gene Gi and Ci=1 if is higher than Ci=−1 lower equal iv) DNARS R v) concluding that treatment when g . = ∑ i 1 n × Ci ( I )
lens.org 参考文章(64)
Roberto Chiarle, Translocations in Normal B Cells and Cancers Advances in Immunology. ,vol. 117, pp. 39- 71 ,(2013) , 10.1016/B978-0-12-410524-9.00002-5
Louis M. Staudt, Sandeep Dave, The Biology of Human Lymphoid Malignancies Revealed by Gene Expression Profiling Advances in Immunology. ,vol. 87, pp. 163- 208 ,(2005) , 10.1016/S0065-2776(05)87005-1
Janet Stavnezer, Andrea Björkman, Likun Du, Alberto Cagigi, Qiang Pan-Hammarström, Mapping of switch recombination junctions, a tool for studying DNA repair pathways during immunoglobulin class switching. Advances in Immunology. ,vol. 108, pp. 45- 109 ,(2010) , 10.1016/B978-0-12-380995-7.00003-3
N J Curtin, Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer. British Journal of Pharmacology. ,vol. 169, pp. 1745- 1765 ,(2013) , 10.1111/BPH.12244
Jérôme Moreaux, Bernard Klein, Methods for predicting multiple myeloma treatment response ,(2013)
James T. Stivers, Daniel J. Krosky, Yu Lin Jiang, Inhibitors of dna repair enzymes and methods of use thereof ,(2006)
W Klapper, H Stoecklein, S Zeynalova, G Ott, F Kosari, A Rosenwald, M Loeffler, L Trümper, M Pfreundschuh, Reiner Siebert, Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia. ,vol. 22, pp. 2226- 2229 ,(2008) , 10.1038/LEU.2008.230
Andreas Rosenwald, George Wright, Wing C. Chan, Joseph M. Connors, Elias Campo, Richard I. Fisher, Randy D. Gascoyne, H. Konrad Muller-Hermelink, Erlend B. Smeland, Jena M. Giltnane, Elaine M. Hurt, Hong Zhao, Lauren Averett, Liming Yang, Wyndham H. Wilson, Elaine S. Jaffe, Richard Simon, Richard D. Klausner, John Powell, Patricia L. Duffey, Dan L. Longo, Timothy C. Greiner, Dennis D. Weisenburger, Warren G. Sanger, Bhavana J. Dave, James C. Lynch, Julie Vose, James O. Armitage, Emilio Montserrat, Armando López-Guillermo, Thomas M. Grogan, Thomas P. Miller, Michel LeBlanc, German Ott, Stein Kvaloy, Jan Delabie, Harald Holte, Peter Krajci, Trond Stokke, Louis M. Staudt, The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma The New England Journal of Medicine. ,vol. 346, pp. 1937- 1947 ,(2002) , 10.1056/NEJMOA012914
Sarah E. Golding, Elizabeth Rosenberg, Nicholas Valerie, Isa Hussaini, Mark Frigerio, Xiaoling F. Cockcroft, Wei Yee Chong, Marc Hummersone, Laurent Rigoreau, Keith A. Menear, Mark J. O'Connor, Lawrence F. Povirk, Timothy van Meter, Kristoffer Valerie, Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion Molecular Cancer Therapeutics. ,vol. 8, pp. 2894- 2902 ,(2009) , 10.1158/1535-7163.MCT-09-0519
S O Yoon, Y K Jeon, J H Paik, W Y Kim, Y A Kim, J E Kim, C W Kim, MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B‐cell lymphoma (DLBCL), especially in germinal centre‐like B cell (GCB) type Histopathology. ,vol. 53, pp. 205- 217 ,(2008) , 10.1111/J.1365-2559.2008.03076.X